Deltex Medical Regulatory News (DEMG)

18 Dec 2006 18:07

Deltex Medical Group PLC18 December 2006 Deltex Medical Group plc CardioQTM reported to reduce length of hospital stay in new types of surgery 19 December 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),the UK's leading haemodynamic monitoring company, today announces thepublication by a leading scientific journal of a letter reporting the results ofthe Medway Maritime NHS Trust's ('Medway') audit into the effectiveness ofTargeted Volume Management ('TVM') using the CardioQ during surgery. The letter, published in the December edition of the British Journal of Surgery,(Volume 93, Issue 12) analyses reductions achieved in length of stay as follows: Type of surgery Per patient bed day saving Bowel resection 2.3 days Gallbladder removal 1.6 days Kidney removal 1.0 day Bladder removal 7.5 days Prostate surgery 1.2 to 2.1 days Broken hip repair 7.8 days Hip replacement 2.2 days Spine surgery 1.5 days The Directors believe that this is the first time that the results of the Medwayaudit, which was undertaken in 2004, have been published by a scientificjournal. Furthermore, the Directors believe that this is the first scientificdata to show TVM improving outcomes in hip replacement, spinal, kidney orprostate surgery. Deltex Medical's chief executive, Andy Hill, commented: "Publication of this letter by a leading medical journal means that, in future,the results of the Medway audit will have to be considered in any review of thescientific literature about the clinical benefits and cost effectiveness of theCardioQ. Medway's results further expand the range of operations where theCardioQ has been shown to benefit patients". For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman nk@deltexmedical.comAndy Hill, Chief Executive ah@deltexmedical.comEwan Phillips, Finance Director ep@deltexmedical.com Gavin Anderson & Company 0207 554 1400 Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457 Philip Davies philip.davies@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQ which have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange